MICRO-X LIMITED (MX1)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

MX1

MX1 - MICRO-X LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -0.43
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.096

10 Sep
2025

0.004

OPEN

$0.10

4.35%

HIGH

$0.10

926,283

LOW

$0.09

TARGET
$0.17 77.1% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CVB . CYC . EBR . EMV . EYE . FPH . IME . IMR . IPD . LDX . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
MX1: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx - 2.3 - 0.9 xxx
DPS (cps) xxx N/A 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 N/A

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx-2.3
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx13.1 M
Book Value Per Share xxxxxxxxxxxxxxx1.1
Net Operating Cash Flow xxxxxxxxxxxxxxx-8.6 M
Net Profit Margin xxxxxxxxxxxxxxx-106.45 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx-128.19 %
Return on Invested Capital xxxxxxxxxxxxxxx-100.67 %
Return on Assets xxxxxxxxxxxxxxx-56.71 %
Return on Equity xxxxxxxxxxxxxxx-128.19 %
Return on Total Capital xxxxxxxxxxxxxxx-104.25 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-8.7 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx4 M
Long Term Debt xxxxxxxxxxxxxxx3 M
Total Debt xxxxxxxxxxxxxxx7 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx3 M
Price To Book Value xxxxxxxxxxxxxxx4.37

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx0.1 M
Capex % of Sales xxxxxxxxxxxxxxx0.77 %
Cost of Goods Sold xxxxxxxxxxxxxxx22 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx8 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

29/08/2025

1

Speculative Buy

$0.17

77.08%

Micro-X missed Morgans' expectations for FY25 with lower product sales versus forecast. The net loss at -$13.3m was a lot higher than the -$8.8m estimated and revenue fell -17.7%. Cash balance stood at $3.2m, the same as the prior year.

A three-year supply agreement for its Rover Plus mobile radiology system was made with a major US healthcare provider in July, its first of this nature, and is considered by Morgans as positive news.

Speculative Buy rating and 17c target unchanged. No major changes were made to the analyst's earnings forecasts and the company is expected to break even in FY27.

FORECAST
Morgans forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -0.90 cents.
Morgans forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -0.20 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Extra Coverage Research History >

MX1 STOCK CHART

FNArena News on MX1

1
Rudi’s View: A Glass Half-Full Outlook

Sep 03 2025 - Rudi's View
2
FNArena Corporate Results Monitor – 29-08-2025

Aug 29 2025 - Australia
3
FNArena Corporate Results Monitor – 29-02-2024

Feb 29 2024 - Australia
4
Dr Boreham’s Crucible: Argenica Therapeutics

Sep 28 2023 - Small Caps
5
FNArena Corporate Results Monitor – 31-08-2023

Aug 31 2023 - Australia

Latest Medical Equipment & Devices News

1
Cochlear’s Future In Nexa’s Hands

Aug 19 2025 - Australia
2
ResMed’s New Level Of Support

Jul 29 2025 - Technicals
3
Strength To ‘AI’ Strength For Pro Medicus

Jul 10 2025 - Australia
4
Cochlear Downgrades Ahead Of New Launches

Jun 19 2025 - Australia
5
Fisher & Paykel Healthcare’s Tariffs Annoyance

Jun 04 2025 - Australia
6
ResMed’s Margin Expansion & Tariff Exemption

Apr 28 2025 - Australia
7
Trend Remains Up For Catapult International

Feb 18 2025 - Technicals
8
ESG Focus: Top ASX Companies, Superbugs & Hydrogen

Feb 07 2025 - ESG Focus
9
ResMed Shakes Off GLP-1 Scare

Feb 04 2025 - Australia
10
ResMed: Another Positive Quarterly Surprise?

Jan 30 2025 - Australia